A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether beatingheart on-pump coronary artery bypass grafting (BH-ONCAB) offered superior mortality and morbidity outcomes when compared with conventional on-pump coronary artery bypass grafting (C-ONCAB). Morbidity outcomes consisted of renal failure, stroke (transient or permanent), myocardial infarction, angina, congestive cardiac failure, reintervention and arrhythmias. Best evidence papers investigating BH-ONCAB versus C-ONCAB were considered. Where data were duplicated, the more credible evidence-based and recently published study was included. Two hundred and thirty-one papers were found using the reported search, of which 11 represented the best evidence to answer the clinical question. Two were prospective randomized controlled trials and the remaining 10 observational studies, of which one was propensity-matched. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Five of these studies demonstrated significantly improved mortality following BH-ONCAB; however, one study exhibited better survival after C-ONCAB. Notably, this study incorporated BH-ONCAB patients with significantly more haemodynamic instability, thus possibly explaining the worse mortality outcomes. In terms of morbidity, a slightly more mixed picture is drawn. Five studies report morbidity in favour of BH-ONCAB, whereas three studies include individual outcomes favouring C-ONCAB. The remaining studies showed equivalent mortality and morbidity data. In summary, the results presented here suggest that BH-ONCAB may improve survival following coronary artery bypass surgery. A key observation is that the greatest benefits of BH-ONCAB appear to be in studies including patients with considerably higher risk characteristics at the time of surgery (haemodialysis, end-stage coronary artery disease, emergency surgery, low ejection fraction). There are limitations of the current evidence presented. Only two studies were randomized controlled trials. There was variability in sample size, selection criteria and preoperative risk profiles between the studies. The studies span many years, and the outcomes may have been affected by evolving technologies and differing patient profiles between these periods.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
THREE-PART QUESTION
In ( patients undergoing on-pump coronary artery bypass grafting surgery) is (the beating-heart or conventional cardioplegic arrest) superior in terms of (mortality and morbidity outcomes)?
CLINICAL SCENARIO
A 72-year old gentleman is referred to the local cardiologist with chest pain on exertion. Coronary angiogram demonstrates significant triple-vessel disease, and angioplasty fails to achieve a successful result. He is continued on medical therapy. A subsequent transthoracic echo demonstrates moderate left ventricular impairment. His case is discussed at the multidisciplinary team meeting, where you are asked to consider him for coronary artery bypass surgery (CABG). Your trainee has recently studied the beating-heart on-pump CABG (BH-ONCAB) technique, and suggests that it might lead to improved outcomes. You therefore appraise the literature to determine the optimal surgical strategy in this patient. AND ('cardiopulmonary bypass'*, 'on-pump', 'cardioplegia') AND ('coronary artery bypass'*) AND ('survival'*, 'mortality'*, 'morbidity'*, 'postoperative complications'*, 'outcomes'*). MeSH terms are indicated with an asterisk. Related citations were also assessed for suitable articles.
SEARCH OUTCOME
A total of 231 papers were found using the reported search. From these, 11 papers were identified to provide the best evidence to answer the clinical question. Outcomes of interest included both mortality (early or late) and morbidity (including renal failure, stroke, myocardial infarction, angina, congestive cardiac failure, reintervention and arrhythmias). These are presented in Table 1 .
RESULTS
Edgerton et al. [2] studied mortality and various morbidity outcomes for four revascularization techniques, including 364 BH-ONCAB and 2332 C-ONCAB patients. Preoperatively, BH-ONCAB patients were determined to have significantly poorer characteristics, and this may in part explain higher rates of mortality and renal failure. Levels of significance were used to compare all four surgical categories, and so there is difficulty in establishing the superiority of either BH-ONCAB or C-ONCAB. However, other outcomes were comparable, and the authors concluded that BH-ONCAB was a safe procedure for unstable patients. Erkut et al. [3] examined BH-ONCAB versus C-ONCAB in patients with a low ejection fraction (EF). BH-ONCAB utilized a suction stabilizer for regional heart immobilization, and the distal anastomosis was completed before the proximal anastomosis. Despite including fewer than 100 patients in either category, BH-ONCAB conferred significantly better mortality and morbidity outcomes.
Similarly, Izumi et al. [4] found significantly better survival and fewer cases of renal failure in 15 BH-ONCAB patients undergoing emergency surgery for acute myocardial infarction (MI). It is notable, however, that BH-ONCAB procedures were performed at a slightly later time period than C-ONCAB. Similarly to the technique employed by Erkut et al., BH-ONCAB utilized a cardiac stabilizer and positioner during grafting, and the left anterior descending artery was the first target vessel for anastomosis.
Mizutani et al. [5] propensity-matched 114 patients; however, BH-ONCAB patients had significantly less complete revascularization compared with C-ONCAB. BH-ONCAB patients had significantly improved survival, but a greater proportion suffered from postoperative atrial fibrillation. There were comparable stroke and renal failure outcomes.
In their prospective, randomized study of 40 BH-ONCAB and 41 C-ONCAB patients, Narayan et al. [6] demonstrated comparable primary and secondary outcomes for mortality, event-free survival, MI and arrhythmias. However, although 5-year outcome data are reported, these are challenging to interpret, as it is difficult to determine the events attributable to each ONCAB group for MI and repeat revascularization.
Pegg et al. [7] also investigated differences between isolated BH-ONCAB and C-ONCAB using a randomized controlled trial incorporating 25 patients in either group with an EF <54%. Although 30-day mortality and major adverse events were similar, there was a significantly higher incidence of new irreversible myocardial injury in BH-ONCAB patients.
Prifti et al. [8] studied 78 BH-ONCAB and C-ONCAB patients with end-stage coronary artery disease. BH-ONCAB was associated with lower postoperative mortality and morbidity, in terms of perioperative MI, postoperative renal dysfunction and ultrafiltration. In their retrospective study, Sabban et al. [9] compared three cardiopulmonary bypass strategies of which 33 cases were performed as BH-ONCAB and 73 as C-ONCAB. The primary focus of the study was neurological and neuropsychological complications. Postoperative deaths were comparable between BH-ONCAB and C-ONCAB; however, there was a trend towards fewer neurological complications in the BH-ONCAB group.
Tarakji et al. [10] performed a large prospective study (234 BH-ONCAB; 18 970 C-ONCAB) focusing on temporal trends in stroke after CABG with the aim of identifying risk factors and associations for peri-and postoperative stroke outcomes. There was no significant difference in stroke between BH-ONCAB (1.7%) and C-ONCAB (1.3%); however, no other outcome data were available.
Tsai et al. [11] investigated outcomes after CABG in haemodialysis patients. The 48 BH-ONCAB patients exhibited significantly improved survival when compared with C-ONCAB, with a trend towards improved freedom from cardiac events and stroke.
Uva et al. [12] retrospectively analysed a total of 241 patients undergoing four different CABG surgical strategies including 47 BH-ONCAB and 66 C-ONCAB. Overall survival and morbidity outcomes were found to be comparable between the two techniques.
CLINICAL BOTTOM LINE
The results of these 11 best evidence studies suggest that BH-ONCAB may offer improved survival following CABG in specific patient sub-groups. A key observation is that four of the five studies favouring BH-ONCAB incorporate patients with a considerably greater preoperative risk profile (haemodialysis, endstage coronary artery disease, emergency surgery, low EF), suggesting that BH-ONCAB confers greater benefit on this patient sub-group.
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